Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Actos Clear all
Withdrawn Phase 2 Interventional

Insulin Resistance and Androgen Deprivation Therapy

NCT04995978
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance
Interventions
Pioglitazone 30 mg, placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

NCT00227110
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 5, 2026, 6:59 PM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Muraglitazar, Pioglitazone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

NCT00782795
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 5, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide in Type 2 Diabetes

NCT00849056
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
310
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Peoria, Arizona • Artesia, California • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes

NCT01223196
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 5, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
110
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 5, 2026, 6:59 PM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and pioglitazone, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2009 · Synced Sep 5, 2026, 6:59 PM EDT
Withdrawn Phase 2 Interventional

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00604578
View directory record Official record
Conditions
Asthma, Airway Inflammation, Airflow Obstruction, Airway Hyperactivity
Interventions
Pioglitazone Hydrochloride
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Effect of Thiazolidinediones on Human Bone

NCT00927355
View directory record Official record
Conditions
Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 5, 2026, 6:59 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 6:59 PM EDT